Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane in CAH/EIN or Low Grade Endometrial Cancer
NCT03300557Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2017
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of exemestane in endometrial hyperplasia (EH), Endometrial intraepithelial neoplasia (EIN), endometrial cancer (EC), sponsored by National Cancer Institute. Started Nov 2017; status: completed.
02
Drugs
exemestane
03
Conditions
endometrial hyperplasia (EH)Endometrial intraepithelial neoplasia (EIN)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03300557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300557.